<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput xmlns:ns2="local" id="2736"><DrugName>cefepime</DrugName><DrugNamesKey><Name id="42764603">Axepim</Name><Name id="42764605">Axepime</Name><Name id="42862285">Cepimax</Name><Name id="42862286">Maxcef</Name><Name id="42862287">Maxipime</Name><Name id="42848050">cefepime</Name><Name id="42862291">cefepime hydrochloride</Name></DrugNamesKey><DrugSynonyms><Name><Value>Axepim</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Axepime</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>cefipime</Value></Name><Name><Value>cefepime</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>BMY-28142</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Cepimax</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Maxcef</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Maxipime</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>cefepime hydrochloride</Value><Types><Type>USAN</Type></Types></Name><Name><Value>88040-23-7</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>123171-59-5</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="15065">Bristol-Myers Squibb Co</CompanyOriginator><CompaniesPrimary><Company id="1010293">Hospira Inc</Company><Company id="15065">Bristol-Myers Squibb Co</Company></CompaniesPrimary><CompaniesSecondary><Company id="15873">Elan Corp plc</Company><Company id="18049">Meiji Seika Pharma Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="2736" type="Drug"><TargetEntity id="90491" type="siDrug">Cefepime</TargetEntity></SourceEntity><SourceEntity id="1010293" type="Company"><TargetEntity id="4295899662" type="organizationId">Hospira Inc</TargetEntity></SourceEntity><SourceEntity id="15065" type="Company"><TargetEntity id="4295903619" type="organizationId">Bristol-Myers Squibb Co</TargetEntity></SourceEntity><SourceEntity id="15873" type="Company"><TargetEntity id="4295874887" type="organizationId">Perrigo Corporation DAC</TargetEntity></SourceEntity><SourceEntity id="18049" type="Company"><TargetEntity id="4295877396" type="organizationId">Meiji Seika Pharma Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1061" type="ciIndication"><TargetEntity id="10040753" type="MEDDRA"></TargetEntity><TargetEntity id="D012852" type="MeSH"></TargetEntity><TargetEntity id="-2064751732" type="omicsDisease"></TargetEntity><TargetEntity id="302" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="114" type="ciIndication"><TargetEntity id="10040047" type="MEDDRA"></TargetEntity><TargetEntity id="D018805" type="MeSH"></TargetEntity><TargetEntity id="-200243460" type="omicsDisease"></TargetEntity><TargetEntity id="953" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="116" type="ciIndication"><TargetEntity id="10051910" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="120" type="ciIndication"><TargetEntity id="D004927" type="MeSH"></TargetEntity><TargetEntity id="-1969770508" type="omicsDisease"></TargetEntity><TargetEntity id="803" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1475" type="ciIndication"><TargetEntity id="A38" type="ICD10"></TargetEntity><TargetEntity id="034.1" type="ICD9"></TargetEntity></SourceEntity><SourceEntity id="1798" type="ciIndication"><TargetEntity id="10054088" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="1815" type="ciIndication"><TargetEntity id="J15" type="ICD10"></TargetEntity><TargetEntity id="10060946" type="MEDDRA"></TargetEntity><TargetEntity id="D018410" type="MeSH"></TargetEntity><TargetEntity id="-2031977293" type="omicsDisease"></TargetEntity><TargetEntity id="928" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="195" type="ciIndication"><TargetEntity id="4198" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2019" type="ciIndication"><TargetEntity id="K81" type="ICD10"></TargetEntity><TargetEntity id="10008612" type="MEDDRA"></TargetEntity><TargetEntity id="D002764" type="MeSH"></TargetEntity><TargetEntity id="-1275543177" type="omicsDisease"></TargetEntity><TargetEntity id="437" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2216" type="ciIndication"><TargetEntity id="K83.0" type="ICD10"></TargetEntity><TargetEntity id="10008604" type="MEDDRA"></TargetEntity><TargetEntity id="D002761" type="MeSH"></TargetEntity><TargetEntity id="-484690873" type="omicsDisease"></TargetEntity><TargetEntity id="435" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2345" type="ciIndication"><TargetEntity id="10044008" type="MEDDRA"></TargetEntity><TargetEntity id="D014069" type="MeSH"></TargetEntity><TargetEntity id="-68262349" type="omicsDisease"></TargetEntity><TargetEntity id="956" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="280" type="ciIndication"><TargetEntity id="804" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="284" type="ciIndication"><TargetEntity id="10037596" type="MEDDRA"></TargetEntity><TargetEntity id="D011704" type="MeSH"></TargetEntity><TargetEntity id="-721934222" type="omicsDisease"></TargetEntity><TargetEntity id="344" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="308" type="ciIndication"><TargetEntity id="4176" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3081" type="ciIndication"><TargetEntity id="10000269" type="MEDDRA"></TargetEntity><TargetEntity id="D000038" type="MeSH"></TargetEntity><TargetEntity id="-473240105" type="omicsDisease"></TargetEntity><TargetEntity id="870" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3082" type="ciIndication"><TargetEntity id="10060921" type="MEDDRA"></TargetEntity><TargetEntity id="D018784" type="MeSH"></TargetEntity><TargetEntity id="-1959458454" type="omicsDisease"></TargetEntity><TargetEntity id="871" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="312" type="ciIndication"><TargetEntity id="10061372" type="MEDDRA"></TargetEntity><TargetEntity id="D013290" type="MeSH"></TargetEntity><TargetEntity id="-669221578" type="omicsDisease"></TargetEntity><TargetEntity id="814" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3653" type="ciIndication"><TargetEntity id="10062233" type="MEDDRA"></TargetEntity></SourceEntity><SourceEntity id="3886" type="ciIndication"><TargetEntity id="10025028" type="MEDDRA"></TargetEntity><TargetEntity id="D008169" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="394" type="ciIndication"><TargetEntity id="10033078" type="MEDDRA"></TargetEntity><TargetEntity id="D010033" type="MeSH"></TargetEntity><TargetEntity id="-2113735649" type="omicsDisease"></TargetEntity><TargetEntity id="898" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="40" type="ciIndication"><TargetEntity id="A49.9" type="ICD10"></TargetEntity><TargetEntity id="10060945" type="MEDDRA"></TargetEntity><TargetEntity id="D001424" type="MeSH"></TargetEntity><TargetEntity id="-1693440076" type="omicsDisease"></TargetEntity><TargetEntity id="800" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="403" type="ciIndication"><TargetEntity id="N30" type="ICD10"></TargetEntity><TargetEntity id="10011781" type="MEDDRA"></TargetEntity><TargetEntity id="D003556" type="MeSH"></TargetEntity><TargetEntity id="-1776447469" type="omicsDisease"></TargetEntity><TargetEntity id="941" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="456" type="ciIndication"><TargetEntity id="4196" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="473" type="ciIndication"><TargetEntity id="N41" type="ICD10"></TargetEntity><TargetEntity id="10036978" type="MEDDRA"></TargetEntity><TargetEntity id="D011472" type="MeSH"></TargetEntity><TargetEntity id="-636590603" type="omicsDisease"></TargetEntity><TargetEntity id="363" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="485" type="ciIndication"><TargetEntity id="D017192" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="1594" type="Action"><TargetEntity id="5353" type="Mechanism">Drugs Targeting Clostridium tetani Proteins</TargetEntity><TargetEntity id="4457" type="Mechanism">Drugs Targeting Staphylococcus aureus Proteins</TargetEntity><TargetEntity id="4493" type="Mechanism">Drugs Targeting Campylobacter jejuni Proteins</TargetEntity><TargetEntity id="1060" type="Mechanism">Efflux Pump (Bacterial) Inhibitors</TargetEntity><TargetEntity id="2409" type="Mechanism">Carbon Monoxide-Releasing Agents</TargetEntity><TargetEntity id="3697" type="Mechanism">Drugs Targeting Escherichia coli Proteins</TargetEntity><TargetEntity id="3994" type="Mechanism">Drugs Targeting Pseudomonas aeruginosa Proteins</TargetEntity><TargetEntity id="5306" type="Mechanism">Drugs Targeting Mycobacterium tuberculosis Proteins</TargetEntity><TargetEntity id="5053" type="Mechanism">Anti-Diphtheria Toxin</TargetEntity><TargetEntity id="4563" type="Mechanism">Anti-Diphteria Toxin (Corynebacterium diphtheriae)</TargetEntity><TargetEntity id="3878" type="Mechanism">Drugs Targeting Bacterial Chaperones</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Abdominal abscess - Japan - Aug-1995</FirstLaunched><FirstLaunched>Abscess - Japan - Aug-1995</FirstLaunched><FirstLaunched>Bacterial infection - Japan - Aug-1995</FirstLaunched><FirstLaunched>Bacterial pneumonia - Japan - Aug-1995</FirstLaunched><FirstLaunched>Bacterial skin infection - Japan - Aug-1995</FirstLaunched><FirstLaunched>Cholangitis - Japan - Aug-1995</FirstLaunched><FirstLaunched>Cholecystitis - Japan - Aug-1995</FirstLaunched><FirstLaunched>Cystitis - Japan - Aug-1995</FirstLaunched><FirstLaunched>Lung abscess - Japan - Aug-1995</FirstLaunched><FirstLaunched>Otitis media - Japan - Aug-1995</FirstLaunched><FirstLaunched>Prostatitis - Japan - Aug-1995</FirstLaunched><FirstLaunched>Pyelonephritis - Japan - Aug-1995</FirstLaunched><FirstLaunched>Sepsis - Japan - Aug-1995</FirstLaunched><FirstLaunched>Sinusitis - Japan - Aug-1995</FirstLaunched><FirstLaunched>Tonsillitis - Japan - Aug-1995</FirstLaunched><FirstLaunched>Uterus infection - Japan - Aug-1995</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="1061">Sinusitis</Indication><Indication id="114">Sepsis</Indication><Indication id="116">Enterobacter infection</Indication><Indication id="120">Escherichia coli infection</Indication><Indication id="1394">Bacteroides fragilis infection</Indication><Indication id="1475">Streptococcus pyogenes infection</Indication><Indication id="1798">Bacterial urinary tract infection</Indication><Indication id="1815">Bacterial pneumonia</Indication><Indication id="195">Klebsiella pneumoniae infection</Indication><Indication id="2019">Cholecystitis</Indication><Indication id="2216">Cholangitis</Indication><Indication id="2345">Tonsillitis</Indication><Indication id="280">Pseudomonas aeruginosa infection</Indication><Indication id="284">Pyelonephritis</Indication><Indication id="308">Staphylococcus aureus infection</Indication><Indication id="3081">Abscess</Indication><Indication id="3082">Abdominal abscess</Indication><Indication id="312">Streptococcus infection</Indication><Indication id="313">Streptococcus pneumoniae infection</Indication><Indication id="3653">Uterus infection</Indication><Indication id="3886">Lung abscess</Indication><Indication id="394">Otitis media</Indication><Indication id="40">Bacterial infection</Indication><Indication id="403">Cystitis</Indication><Indication id="456">Proteus mirabilis infection</Indication><Indication id="473">Prostatitis</Indication><Indication id="485">Bacterial skin infection</Indication></IndicationsPrimary><ActionsPrimary><Action id="66340">Penicillin binding protein inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1535">Beta lactam antibiotic</Action><Action id="15187">Systemic dermatological antibacterial product</Action><Action id="104">Bacterial cell wall synthesis inhibitor</Action><Action id="1537">Cephalosporin</Action><Action id="1594">Antibacterial</Action></ActionsSecondary><Technologies><Technology id="648">Intravenous formulation</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="66">Antibiotic</Technology><Technology id="740">Infusion</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>J1D</Code><Name>CEPHALOSPORINS</Name></Ephmra><Ephmra><Code>J1</Code><Name>SYSTEMIC ANTIBACTERIALS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-01-04T08:08:10.000Z</LastModificationDate><ChangeDateLast>2018-08-20T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Developed and launched by &lt;ulink linkID="15065" linkType="Company"&gt;Bristol-Myers Squibb&lt;/ulink&gt; (BMS) and now marketed in the US by &lt;ulink linkID="1010293" linkType="Company"&gt;Hospira&lt;/ulink&gt; (a subsidiary of &lt;ulink linkID="18767" linkType="Company"&gt;Pfizer&lt;/ulink&gt;), cefepime (Maxipime; Maxcef) is a fourth-generation, semi-synthetic, broad-spectrum cephalosporin antibiotic for parenteral administration [&lt;ulink linkID="882313" linkType="Reference"&gt;882313&lt;/ulink&gt;]. In the US, the drug is indicated as an iv infusion or im injection for the treatment of moderate to severe pneumonia caused by Streptococcus pneumoniae (including cases associated with concurrent bacteremia), Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species; empirical therapy for febrile neutropenic patients; complicated and uncomplicated urinary tract infections, including pyelonephritis, caused by Escherichia coli or K pneumoniae when the infection is severe, or caused by E coli, K pneumoniae or Proteus mirabilis when the infection is mild to moderate, including cases with concurrent bacteremia; uncomplicated skin and skin structure infections caused by methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes; and  in combination with metronidazole for complicated intra-abdominal infections caused by E coli, viridians group streptococci, P aeruginosa, K pneumoniae, Enterobacter species, or Bacteroides fragilis   [&lt;ulink linkID="1657501" linkType="Reference"&gt;1657501&lt;/ulink&gt;]. In Japan, cefepime is indicated for the treatment of sepsis, skin infections, secondary infections of surgical wounds, burns and trauma, peritonsillar abscess, perianal abscess, tonsillitis, pneumonia, lung abscess, secondary infections in chronic respiratory disease, complicated cystitis, pyelonephritis, acute and chronic prostatitis, peritonitis, intra-abdominal abscess, cholecystitis, cholangitis, intrauterine infection, inflammation of the uterine connective tissue, otitis media, sinusitis, and febrile neutropenia [&lt;ulink linkID="1342366" linkType="Reference"&gt;1342366&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Cefepime had been launched in Japan by August 1995 [&lt;ulink linkID="1342366" linkType="Reference"&gt;1342366&lt;/ulink&gt;]. By December 1995, cefepime had been launched in France and Italy [&lt;ulink linkID="177463" linkType="Reference"&gt;177463&lt;/ulink&gt;]. The drug was launched in the US in 3Q96 [&lt;ulink linkID="1342385" linkType="Reference"&gt;1342385&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The product was formerly marketed by &lt;ulink linkID="15873" linkType="Company"&gt;Elan&lt;/ulink&gt; in the US, however, the company discontinued distribution in September 2010 [&lt;ulink linkID="1085997" linkType="Reference"&gt;1085997&lt;/ulink&gt;], [&lt;ulink linkID="1142327" linkType="Reference"&gt;1142327&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;The product patent &lt;ulink linkID="IN1030406" linkType="Patent"&gt;US-04406899&lt;/ulink&gt;, which was originally due to expire on September 27, 2000, had its term reset according to the GATT agreement giving a new expiry date of March 4, 2002. However, this date was further extended due to Hatch-Waxman provisions, providing a further 5 years protection until March 4, 2007. BMS also has further patents protecting injectable compositions and formulations of cefepime, which expiried in January 2008, and processes for producing cefepime dichlorohydrates, which expiried in September 2012, with further extensions possible.&lt;/para&gt;&lt;para&gt;In August 2018, &lt;ulink linkID="1178540" linkType="Company"&gt;Samson Medical Technologies&lt;/ulink&gt; received ANDA approval in the US for its generic version of cefepime for injection (100 g)  [&lt;ulink linkID="2107476" linkType="Reference"&gt;2107476&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="27798" linkType="Company"&gt;Orchid&lt;/ulink&gt; received final approval of an ANDA for cefipime in June 2007. The generic was launched immediately [&lt;ulink linkID="877204" linkType="Reference"&gt;877204&lt;/ulink&gt;].   &lt;/para&gt;&lt;para&gt;In March 2008, &lt;ulink linkID="1034907" linkType="Company"&gt;Sagent Pharmaceuticals&lt;/ulink&gt; and &lt;ulink linkID="27814" linkType="Company"&gt;APP Pharmaceuticals&lt;/ulink&gt; launched generic cefepime for injection formulations in the US [&lt;ulink linkID="888862" linkType="Reference"&gt;888862&lt;/ulink&gt;], [&lt;ulink linkID="889001" linkType="Reference"&gt;889001&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In March 2008, &lt;ulink linkID="21883" linkType="Company"&gt;ACS Dobfar&lt;/ulink&gt; was granted FDA approval for its 1 and 2 g/vial generic version of  cefepime [&lt;ulink linkID="1017330" linkType="Reference"&gt;1017330&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In September 2009, &lt;ulink linkID="30215" linkType="Company"&gt;Aurobindo Pharma&lt;/ulink&gt; was granted approval by Swissmedic for cefepime 1 and 2 g injections  in Switzerland [&lt;ulink linkID="1041251" linkType="Reference"&gt;1041251&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;Cefepime was approved in the US in early 1996 [&lt;ulink linkID="1342376" linkType="Reference"&gt;1342376&lt;/ulink&gt;]. The drug was launched in the US in 3Q96 [&lt;ulink linkID="1342385" linkType="Reference"&gt;1342385&lt;/ulink&gt;].   &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;By December 1995, cefepime had been launched in France and Italy, and approved in Switzerland and Ireland [&lt;ulink linkID="177463" linkType="Reference"&gt;177463&lt;/ulink&gt;]; it was presumably launched shortly after approval in Switzerland and Ireland. Cefepime was approved in the UK in May 1996 [&lt;ulink linkID="202996" linkType="Reference"&gt;202996&lt;/ulink&gt;]; it was presumably launched shortly after approval .&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;The drug had been launched in Japan by August 1995 [&lt;ulink linkID="1342366" linkType="Reference"&gt;1342366&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In November 2001, cefepime       was approved in China; the product had been launched in China by October 2005 [&lt;ulink linkID="1290156" linkType="Reference"&gt;1290156&lt;/ulink&gt;], [&lt;ulink linkID="1290157" linkType="Reference"&gt;1290157&lt;/ulink&gt;], [&lt;ulink linkID="1290161" linkType="Reference"&gt;1290161&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;By December 1995, cefepime had been launched in Canada [&lt;ulink linkID="206604" linkType="Reference"&gt;206604&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;By December 1995, cefepime had been launched in  Argentina [&lt;ulink linkID="206604" linkType="Reference"&gt;206604&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 1995, cefepime had been launched in  Venezuela [&lt;ulink linkID="206604" linkType="Reference"&gt;206604&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 1995, cefepime had been approved, and presumably launched, in Brazil [&lt;ulink linkID="206604" linkType="Reference"&gt;206604&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 1995, cefepime had been approved, and presumably launched,  in  Mexico [&lt;ulink linkID="206604" linkType="Reference"&gt;206604&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Middle East and Africa&lt;/subtitle&gt;By December 1995, cefepime had been launched in South Africa [&lt;ulink linkID="206604" linkType="Reference"&gt;206604&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;In November 2007, the FDA advocated caution when prescribing cefepime after a  journal article found a higher level of mortality due to all causes in patients receiving the drug compared with other beta lactam antibiotics. The Agency began reviewing safety data and  requested additional information to evaluate the risk of death [&lt;ulink linkID="966866" linkType="Reference"&gt;966866&lt;/ulink&gt;]. In June 2009, the FDA completed its review of the data and found no increased mortality associated with cefepime. At that time, the FDA and BMS were continuing safety analyses of cefepime [&lt;ulink linkID="1061080" linkType="Reference"&gt;1061080&lt;/ulink&gt;]. In June 2012, the FDA reported that the label was being revised to highlight the risk of non-convulsive status epilepticus associated with cefepime, particularly in patients with renal impairment [&lt;ulink linkID="1304740" linkType="Reference"&gt;1304740&lt;/ulink&gt;].   &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;A phase IV study (&lt;ulink linkID="11249" linkType="Protocol"&gt;NCT00358202&lt;/ulink&gt;) was carried out between March 2002 and April 2006. The trial enrolled 69 patients, and was designed to assess if im cefepime was a safe, efficacious and cost-effective alternative to once daily im &lt;ulink linkID="44384" linkType="Drug"&gt;ceftriaxone&lt;/ulink&gt; for the treatment of elderly nursing home residents with pneumonia [&lt;ulink linkID="966861" linkType="Reference"&gt;966861&lt;/ulink&gt;]. Data from the study were published in May 2007. Clinical success was observed in 78 and 66% of cefepime- and ceftriaxone-treated patients, respectively. Cefepime was associated with significantly lower costs compared with ceftriaxone [&lt;ulink linkID="1342291" linkType="Reference"&gt;1342291&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 1997, a multicenter, randomized, open-label, evaluator-blind study began in Europe to compare the efficacy of cefepime compared with &lt;ulink linkID="44406" linkType="Drug"&gt;imipenem-cilastatin&lt;/ulink&gt; for the treatment of hospitalized patients with nosocomial pneumonia (n = 281). The study was completed in May 1999. Data from the study were published in November 2003. The clinical response rates were 70 and 74% for cefepime and imipenem-cilastatin, respectively. Drug-related adverse events were more frequent in the cefepime group   [&lt;ulink linkID="1342297" linkType="Reference"&gt;1342297&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Febrile neutropenia&lt;/subtitle&gt;The safety and efficacy of empiric cefepime monotherapy for febrile neutropenic patients was assessed in two multicenter, randomized trials, comparing cefepime monotherapy (2 g iv q8h) to &lt;ulink linkID="44317" linkType="Drug"&gt;ceftazidime&lt;/ulink&gt; monotherapy (2 g iv q8h). These studies comprised 317 evaluable patients. For all outcome measures, cefepime was therapeutically equivalent to ceftazidime, with a 34% versus 39% response rate, respectively, for the resolution of primary episode without the need for further antibiotics [&lt;ulink linkID="482548" linkType="Reference"&gt;482548&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 1995, a multicenter, randomized study began in France to compare the efficacy of cefepime with &lt;ulink linkID="44406" linkType="Drug"&gt;imipenem-cilastatin&lt;/ulink&gt; in febrile patients with short duration neutropenia (n =  400). The study completed in November 1996. Data from the study were published in October 1998. The response rates were 79 and 72% for cefepime and imipenem-cilastatin, respectively. The incidence of drug-related adverse events was significantly lower in the cefepime group compared with the imipenem-cilastatin group [&lt;ulink linkID="1342312" linkType="Reference"&gt;1342312&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Complicated intra-abdominal infections&lt;/subtitle&gt;Patients hospitalized with complicated intra-abdominal infections participated in a randomized, double-blind, multicenter trial comparing the combination of cefepime (2 g q12h) plus iv &lt;ulink linkID="55388" linkType="Drug"&gt;metronidazole&lt;/ulink&gt; (500 mg q6h) versus &lt;ulink linkID="44406" linkType="Drug"&gt;imipenem-cilastatin&lt;/ulink&gt; (500 mg q6h) for a maximum duration of 14 days. The study was designed to demonstrate equivalence.  The overall clinical cure rate was 81% in the cefepime plus metronidazole group and 66% in the imipenem-cilastatin group [&lt;ulink linkID="482548" linkType="Reference"&gt;482548&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In June 2017, in vitro data from a study   conducted as part of the TEST program were presented at the 2017 ASM Microbe Conference in New Orleans, LA. For P aeruginosa collected from United States (n = 2545), Canada (n = 687), Mexico (n = 236), Colombia (n = 122), Chile (n = 110), Panama (n = 87), Brazil (n = 63), Argentina (n = 62), Venezuela (n = 58) and Guatemala (n = 43), the percentage of susceptibility to cefipime was 81.1, 78.5, 77.1, 63.9, 67.3, 63.2, 69.8, 75.8, 60.3 and 18.6%, respectively; and MIC50/90 values were 4/16, 4/16, 4/&amp;gt;32, 4/&amp;gt;32, 4/&amp;gt;32, 4/&amp;gt;32, 4/&amp;gt;32, 4/32, 4/32 and 32/&amp;gt;32 microg/ml, respectively. Overall, against P aeruginosa, cefepime was less active compared to amikacin [&lt;ulink linkID="1934248" linkType="Reference"&gt;1934248&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2017, results from in vitro studies conducted as part of the Tigecycline European Surveillance Trial (TEST) program were presented at the 27th ECCMID in Vienna, Austria. For Enterobacteriaceae isolates collected from Spain (n = 6464), Italy (n = 5350), Germany (n = 5275), France (n = 4087), Belgium (n = 2224), Portugal (n = 1308), Switzerland (n = 999), United Kingdom (n = 828), Ireland (n = 580) and the Netherlands (n = 540) from 2013 to 2016, percentage susceptibility (%)/MIC90 (microg/ml) values were 81.1/16, 66.6/&amp;gt; 32, 84.0/8, 76.4/32, 82.0/8, 75.2/32, 89.1/2, 87.8/2, 68.5/&amp;gt; 32 and 93.9/&amp;lt;/= 0.5 for cefipime and 82.6/64, 73.4/ &amp;gt; 128, 85.2/32, 81.5/32, 79.8/64, 73.7/128, 89.5/16, 87.0/32, 74.8/64 and 92.2/8 for piperacillin + tazobactam, respectively [&lt;ulink linkID="1920445" linkType="Reference"&gt;1920445&lt;/ulink&gt;].  Further preclinical data were presented at the same conference. Overall, against P aeruginosa, piperacillin-tazobactam showed more activity relative to meropenem, comparable activity to ceftazidime and cefepime, but was less active compared to amikacin [&lt;ulink linkID="1920419" linkType="Reference"&gt;1920419&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2016, preclinical data were presented at the 2016 ASM Microbe Conference in Boston, MA. The survival rates were improved and were significantly higher in mice which were treated with combination therapy (&lt;ulink linkID="91223" linkType="Drug"&gt;OP-0595&lt;/ulink&gt; and cefepime) compared with others. Against ESBL-Kpn and pharmacokinetic analysis, the %time &amp;gt; MIC for 4, 20 and 100 mg/kg dose cefepime  and 20 mg/kg of OP-0595 alone were  0, 3.1, 9.6 and 6.5%, respectively, and those for all combinations were 14.1% [&lt;ulink linkID="1771483" linkType="Reference"&gt;1771483&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; In April 2016, preclinical data were presented at the 26th ECCMID in Amsterdam, the Netherlands. Against Enterobacteriaceae and Pseudomonas aeruginosa, the in vitro activity of &lt;ulink linkID="29446" linkType="Drug"&gt;piperacillin-tazobactam&lt;/ulink&gt;, &lt;ulink linkID="52596" linkType="Drug"&gt;amikacin&lt;/ulink&gt;, cefepime, ceftazidime, &lt;ulink linkID="3492" linkType="Drug"&gt;levofloxacin&lt;/ulink&gt;, &lt;ulink linkID="3616" linkType="Drug"&gt;meropenem&lt;/ulink&gt;, and &lt;ulink linkID="8642" linkType="Drug"&gt;tigecycline&lt;/ulink&gt;  varied to varying degrees from one European country to another [&lt;ulink linkID="1750199" linkType="Reference"&gt;1750199&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Supply shortages occurred in 1Q05 but were expected to return to normal by May 2005 [&lt;ulink linkID="598309" linkType="Reference"&gt;598309&lt;/ulink&gt;]; by that time Elan was closely monitoring supply levels [&lt;ulink linkID="614720" linkType="Reference"&gt;614720&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="206604" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-10-25T00:00:00.000Z</StatusDate><Source id="1290161" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-10-25T00:00:00.000Z</StatusDate><Source id="1290161" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3081">Abscess</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-08-31T00:00:00.000Z</StatusDate><Source id="1342376" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="394">Otitis media</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-08-31T00:00:00.000Z</StatusDate><Source id="1342376" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1010293">Hospira Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-12-21T00:00:00.000Z</StatusDate><Source id="1352566" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1010293">Hospira Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1475">Streptococcus pyogenes infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-12-21T00:00:00.000Z</StatusDate><Source id="1352566" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="206604" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1010293">Hospira Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-12-21T00:00:00.000Z</StatusDate><Source id="1352566" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-06-30T00:00:00.000Z</StatusDate><Source id="176853" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-08-31T00:00:00.000Z</StatusDate><Source id="1342376" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2019">Cholecystitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-08-31T00:00:00.000Z</StatusDate><Source id="1342376" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="473">Prostatitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-08-31T00:00:00.000Z</StatusDate><Source id="1342376" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-08-31T00:00:00.000Z</StatusDate><Source id="1342376" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2216">Cholangitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-08-31T00:00:00.000Z</StatusDate><Source id="1342376" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1010293">Hospira Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-12-21T00:00:00.000Z</StatusDate><Source id="1352566" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1010293">Hospira Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="280">Pseudomonas aeruginosa infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-12-21T00:00:00.000Z</StatusDate><Source id="1352566" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="GB">UK</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-11-07T00:00:00.000Z</StatusDate><Source id="202996" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-08-31T00:00:00.000Z</StatusDate><Source id="1342376" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3653">Uterus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-08-31T00:00:00.000Z</StatusDate><Source id="1342376" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1010293">Hospira Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-12-21T00:00:00.000Z</StatusDate><Source id="1352566" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-08-31T00:00:00.000Z</StatusDate><Source id="1342376" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3082">Abdominal abscess</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-08-31T00:00:00.000Z</StatusDate><Source id="1342376" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="403">Cystitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-08-31T00:00:00.000Z</StatusDate><Source id="1342376" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1010293">Hospira Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="313">Streptococcus pneumoniae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-12-21T00:00:00.000Z</StatusDate><Source id="1352566" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1010293">Hospira Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="120">Escherichia coli infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-12-21T00:00:00.000Z</StatusDate><Source id="1352566" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-10-25T00:00:00.000Z</StatusDate><Source id="1290161" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="IT">Italy</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="177463" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="3886">Lung abscess</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-08-31T00:00:00.000Z</StatusDate><Source id="1342376" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1010293">Hospira Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1394">Bacteroides fragilis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-12-21T00:00:00.000Z</StatusDate><Source id="1352566" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1010293">Hospira Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="195">Klebsiella pneumoniae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-12-21T00:00:00.000Z</StatusDate><Source id="1352566" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="206604" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-08-31T00:00:00.000Z</StatusDate><Source id="1342376" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-10-25T00:00:00.000Z</StatusDate><Source id="1290161" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-10-25T00:00:00.000Z</StatusDate><Source id="1290161" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1061">Sinusitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-08-31T00:00:00.000Z</StatusDate><Source id="1342376" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="VE">Venezuela</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="206604" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1010293">Hospira Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-12-21T00:00:00.000Z</StatusDate><Source id="1352566" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1010293">Hospira Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="116">Enterobacter infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-12-21T00:00:00.000Z</StatusDate><Source id="1352566" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2345">Tonsillitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-08-31T00:00:00.000Z</StatusDate><Source id="1342376" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="177463" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="206604" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1010293">Hospira Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="312">Streptococcus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-12-21T00:00:00.000Z</StatusDate><Source id="1352566" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1010293">Hospira Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="456">Proteus mirabilis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-12-21T00:00:00.000Z</StatusDate><Source id="1352566" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1010293">Hospira Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-12-21T00:00:00.000Z</StatusDate><Source id="1352566" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-10-25T00:00:00.000Z</StatusDate><Source id="1290161" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1010293">Hospira Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2012-12-21T00:00:00.000Z</StatusDate><Source id="1352566" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="177463" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="206604" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-06-30T00:00:00.000Z</StatusDate><Source id="206604" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="116">Enterobacter infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2010-09-30T00:00:00.000Z</StatusDate><Source id="1142327" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2010-09-30T00:00:00.000Z</StatusDate><Source id="1142327" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="195">Klebsiella pneumoniae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2010-09-30T00:00:00.000Z</StatusDate><Source id="1142327" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="284">Pyelonephritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2010-09-30T00:00:00.000Z</StatusDate><Source id="1142327" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2010-09-30T00:00:00.000Z</StatusDate><Source id="1142327" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="312">Streptococcus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2010-09-30T00:00:00.000Z</StatusDate><Source id="1142327" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1394">Bacteroides fragilis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2010-09-30T00:00:00.000Z</StatusDate><Source id="1142327" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="313">Streptococcus pneumoniae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2010-09-30T00:00:00.000Z</StatusDate><Source id="1142327" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="456">Proteus mirabilis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2010-09-30T00:00:00.000Z</StatusDate><Source id="1142327" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2010-09-30T00:00:00.000Z</StatusDate><Source id="1142327" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2010-09-30T00:00:00.000Z</StatusDate><Source id="1142327" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2010-09-30T00:00:00.000Z</StatusDate><Source id="1142327" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="120">Escherichia coli infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2010-09-30T00:00:00.000Z</StatusDate><Source id="1142327" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="280">Pseudomonas aeruginosa infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2010-09-30T00:00:00.000Z</StatusDate><Source id="1142327" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2010-09-30T00:00:00.000Z</StatusDate><Source id="1142327" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1475">Streptococcus pyogenes infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2010-09-30T00:00:00.000Z</StatusDate><Source id="1142327" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1394">Bacteroides fragilis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-31T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="456">Proteus mirabilis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-31T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="280">Pseudomonas aeruginosa infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-31T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="120">Escherichia coli infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-31T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="116">Enterobacter infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-31T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="195">Klebsiella pneumoniae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-31T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-31T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="312">Streptococcus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-31T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-31T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1475">Streptococcus pyogenes infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-31T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-31T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-31T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-31T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-31T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-31T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="313">Streptococcus pneumoniae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-31T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-11-22T00:00:00.000Z</StatusDate><Source id="1290156" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-11-22T00:00:00.000Z</StatusDate><Source id="1290156" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-11-22T00:00:00.000Z</StatusDate><Source id="1290156" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-11-22T00:00:00.000Z</StatusDate><Source id="1290156" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-11-22T00:00:00.000Z</StatusDate><Source id="1290156" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2001-11-22T00:00:00.000Z</StatusDate><Source id="1290156" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1010293">Hospira Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-01-18T00:00:00.000Z</StatusDate><Source id="1484863" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="GB">UK</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-05-07T00:00:00.000Z</StatusDate><Source id="202996" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="IE">Ireland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="206604" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="177463" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="206604" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="206604" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1995-12-31T00:00:00.000Z</StatusDate><Source id="191886" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18049">Meiji Seika Pharma Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><Source id="180770" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-06-30T00:00:00.000Z</StatusDate><Source id="1342376" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-01-01T00:00:00.000Z</StatusDate><Source id="196811" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-01-01T00:00:00.000Z</StatusDate><Source id="196811" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-15T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1815">Bacterial pneumonia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-15T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="313">Streptococcus pneumoniae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-15T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-15T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="280">Pseudomonas aeruginosa infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-15T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="195">Klebsiella pneumoniae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-15T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="116">Enterobacter infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-15T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1798">Bacterial urinary tract infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-15T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-15T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="120">Escherichia coli infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-15T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="456">Proteus mirabilis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-15T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-15T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-15T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1475">Streptococcus pyogenes infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-15T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="312">Streptococcus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-15T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15873">Elan Corp plc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1394">Bacteroides fragilis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1999-01-15T00:00:00.000Z</StatusDate><Source id="882313" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="485">Bacterial skin infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-09-30T00:00:00.000Z</StatusDate><Source id="1342385" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="312">Streptococcus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-09-30T00:00:00.000Z</StatusDate><Source id="1342385" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1475">Streptococcus pyogenes infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-09-30T00:00:00.000Z</StatusDate><Source id="1342385" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="308">Staphylococcus aureus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-09-30T00:00:00.000Z</StatusDate><Source id="1342385" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="456">Proteus mirabilis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-09-30T00:00:00.000Z</StatusDate><Source id="1342385" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="120">Escherichia coli infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-09-30T00:00:00.000Z</StatusDate><Source id="1342385" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-09-30T00:00:00.000Z</StatusDate><Source id="1342385" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="280">Pseudomonas aeruginosa infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-09-30T00:00:00.000Z</StatusDate><Source id="1342385" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="313">Streptococcus pneumoniae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-09-30T00:00:00.000Z</StatusDate><Source id="1342385" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="195">Klebsiella pneumoniae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-09-30T00:00:00.000Z</StatusDate><Source id="1342385" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="116">Enterobacter infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-09-30T00:00:00.000Z</StatusDate><Source id="1342385" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="284">Pyelonephritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-09-30T00:00:00.000Z</StatusDate><Source id="1342385" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="114">Sepsis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1996-01-01T00:00:00.000Z</StatusDate><Source id="196811" type="SERIAL"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-11672"><Name>Penicillin binding protein</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2107476" linkType="reference" linkID="2107476"&gt;2107476&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1091305">Perrigo Co plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="15065">Bristol-Myers Squibb Co</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="18767">Pfizer Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[N+]1(CCCC1)CC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/c4csc(n4)N)SC2)C(=O)[O-]</Smiles><Smiles>C[N+]1(CCCC1)CC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/c4csc(n4)N)SC2)C(=O)O.O.Cl.[Cl-]</Smiles></StructureSmiles><Deals><Deal id="119804" title="Elan and Bristol-Myers Squibb to comarket cefepime in the US"></Deal><Deal id="148158" title="Hospira to acquire Bristol-Myers Squibb's cefepime "></Deal></Deals><PatentFamilies><PatentFamily id="1027418" number="WO-2004092183" title="Cefepime processes"></PatentFamily><PatentFamily id="108853" number="WO-2007129176" title="Improvements in therapy for treating resistant bacterial infections"></PatentFamily><PatentFamily id="1176534" number="WO-2006006040" title="News salts in the preparation of cephalosporin antibiotics"></PatentFamily><PatentFamily id="1235058" number="WO-2005019227" title="Process for the preparation of cephalosporin antibiotic"></PatentFamily><PatentFamily id="1249770" number="WO-2006064516" title="Antibiotic combinations for providing total solution to the treatment of infections"></PatentFamily><PatentFamily id="1309471" number="WO-2007086011" title="Formulation comprising cefepime, tazobactam and linezolid"></PatentFamily><PatentFamily id="1394311" number="KR-2005029342" title="Crystalline cefepime dihydrochloride hemihydrate having wide range of antibiotic spectrum and improved water-solubility and storage stability and process for preparation thereof"></PatentFamily><PatentFamily id="1439473" number="WO-2006106529" title="A co-spray dried composition of cefepime with base and process for preparation thereof"></PatentFamily><PatentFamily id="1440735" number="WO-2007016134" title="Bicyclic 6-alkylidene-penem β-lactamase inhibitors and β-lactam antibiotic combination: a broad spectrum antibiotic"></PatentFamily><PatentFamily id="147426" number="CN-101337971" title="Method for synthesizing antibiotic cefepime hydrochloride"></PatentFamily><PatentFamily id="1561463" number="CN-102675345" title="Preparation method of cefepime hydrochloride"></PatentFamily><PatentFamily id="1563709" number="IN-200501423" title="Improved process for preparation of cefepime comprises reacting compound in the presence of a base and dimethylformamide, optionally in presence of water"></PatentFamily><PatentFamily id="1586347" number="WO-2005094800" title="A co-precipitated cefepime composition and process for preparation thereof"></PatentFamily><PatentFamily id="1623284" number="WO-2006109324" title="Processes for preparation of amorphous cefepime acid addition salts"></PatentFamily><PatentFamily id="1659407" number="US-20050043531" title="Process for preparing cefepime"></PatentFamily><PatentFamily id="1664429" number="WO-2009004463" title="Improved process for the preparation of cefepime intermediate"></PatentFamily><PatentFamily id="177930" number="EP-01832593" title="Direct process for the production of sterile cefepime dihydrochloride monohydrate"></PatentFamily><PatentFamily id="182613" number="WO-2007065288" title="Useful combinations of monobactam antibiotics with beta-lactamase inhibitors"></PatentFamily><PatentFamily id="1881282" number="WO-2005063772" title="Process for production of intermediates for use in cefalosporin synthesis"></PatentFamily><PatentFamily id="1884059" number="WO-2007027323" title="Tricyclic 6-alkylidene-penem β-lactamase inhibitors and β-lactam antibiotic combination: a broad spectrum antibiotic"></PatentFamily><PatentFamily id="1927306" number="IN-00218500" title="Improved process for the preparation of cefepime involves acylation of amine compound or its salts in aqueous acetone, with 2-mercaptobenzothiazolyl ester in the presence of a base"></PatentFamily><PatentFamily id="1985182" number="WO-2009111422" title="Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens"></PatentFamily><PatentFamily id="2084221" number="US-04406899" title="Cephalosporins"></PatentFamily><PatentFamily id="2105134" number="WO-2006067803" title="A novel intermediate for the preparation of cefepime"></PatentFamily><PatentFamily id="2267134" number="CN-100418972" title="Cephe alkene onium salt compound and its preparation and use in preparation of cefepime"></PatentFamily><PatentFamily id="2297802" number="WO-2011121389" title="Process for preparation of cefepime dihydrochloride monohydrate"></PatentFamily><PatentFamily id="2358660" number="WO-2006008749" title="Process for preparing pure cephalosporine intermediates"></PatentFamily><PatentFamily id="2378345" number="US-04910301" title="Cefepime cephalosporin salts."></PatentFamily><PatentFamily id="2393041" number="CN-102743388" title="Composition used for inhibiting bacteria generating novel beta lactamase"></PatentFamily><PatentFamily id="2421793" number="WO-2012164358" title="Compositions comprising antibacterial agent and tazobactam"></PatentFamily><PatentFamily id="2572981" number="WO-2013114319" title="Process for the direct preparation of cefepime for injectable use"></PatentFamily><PatentFamily id="2825669" number="CN-103983775" title="A receptor-based detection of β-lactam antibiotics immunochromatographic strip and its preparation method"></PatentFamily><PatentFamily id="2925485" number="WO-2015059643" title="Pharmaceutical compositions comprising antibacterial agents"></PatentFamily><PatentFamily id="2995856" number="WO-2015125031" title="Pharmaceutical combinations comprising antibacterial agents"></PatentFamily><PatentFamily id="3059091" number="US-09597319" title="Compositions and methods of inhibiting metallo-&amp;#946;-lactamases"></PatentFamily><PatentFamily id="3199661" number="WO-2016086161" title="Intestinal microbiota and GvHD"></PatentFamily><PatentFamily id="330873" number="EP-01762570" title="Process for producing the cefepime dihydrochloride monohydrate"></PatentFamily><PatentFamily id="3576470" number="WO-2017045019" title="Antibiotic therapy"></PatentFamily><PatentFamily id="3604509" number="WO-2017064670" title="Treatment for infection composed of menstrual stem cells"></PatentFamily><PatentFamily id="3732044" number="CN-106928268" title="Method of preparing iodotrimethylsilane"></PatentFamily><PatentFamily id="3780467" number="WO-2017156037" title="Methods and systems for determining antibiotic susceptibility"></PatentFamily><PatentFamily id="3787906" number="EP-03216873" title="Combination of structural variations and single nucleotide changes in one statistical model for improved therapy selection"></PatentFamily><PatentFamily id="379339" number="CN-101623260" title="Cefepime hydrochloride proliposome preparation"></PatentFamily><PatentFamily id="3820803" number="WO-2017178558" title="Using the full repertoire of genetic information from bacterial genomes and plasmids for improved genetic resistance tests"></PatentFamily><PatentFamily id="387703" number="GB-02199746" title="Antibiotic compositions"></PatentFamily><PatentFamily id="4004418" number="CN-107854719" title="A double wound medicine-carrying antibacterial dressing and preparation method thereof"></PatentFamily><PatentFamily id="4089550" number="IN-201611041230" title="Impedimetric sensing method for detection of trace levels of beta-lactam antibiotics in forensic samples (blood, gastric lavage and viscera), involves using enzyme bound nanohybrid film"></PatentFamily><PatentFamily id="4191046" number="WO-2018165048" title="Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof"></PatentFamily><PatentFamily id="4194380" number="CN-108498519" title="An anti-infective compound, preparation and application thereof"></PatentFamily><PatentFamily id="4239899" number="WO-2018193369" title="Antibacterial compositions"></PatentFamily><PatentFamily id="4461859" number="WO-2019070739" title="Apparatus, systems, and methods for determining the concentration of microorganisms and the susceptibility of microorganisms to anti-infectives based on redox reactions"></PatentFamily><PatentFamily id="490819" number="CN-100416272" title="Process for preparing comparison solution for measuring polymeric substance in cefepime, its salt raw material and preparation"></PatentFamily><PatentFamily id="491169" number="CN-100453545" title="Method of synthesizing cefepime intermediate in mixed solvent"></PatentFamily><PatentFamily id="599940" number="WO-2011012790" title="Media for the specific detection of Gram-negative bacteria resistant to beta-lactam antibiotics"></PatentFamily><PatentFamily id="604061" number="US-04680389" title="Temperature Stable Crystalline Di(1-Methyl-2-Pyrralidinone) And Di(N-Formylpyrrolidine) Adducts Of Cephalosporin Derivatives"></PatentFamily><PatentFamily id="675872" number="EP-00533047" title="Preparation of a cephalosporin antibiotic using the synisomer of a thiazolyl intermediate"></PatentFamily><PatentFamily id="722348" number="EP-00531981" title="Process for the preparation of a cephalosporin antibiotic."></PatentFamily><PatentFamily id="74521" number="WO-2009095387" title="Use of inhibitor of β-lactamases and its combination with β-lactam antibiotics"></PatentFamily><PatentFamily id="90099" number="EP-00386668" title="Lyophilized dihydrochloride of 7-(alpha-(2-aminothI azol-4-yl)-alpha-(z) -methoxyiminoacetami do)-3-((1-methyl-1-pyrrolidinium)-methyl)-3-cephem-4-carboxylate."></PatentFamily><PatentFamily id="953313" number="WO-2006075244" title="Improved process for the preparation of cephalosporin antibiotic intermediate"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="1">Analyte</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>16</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>18</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>12</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>5</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jinan University (Guangdong)" id="1019449"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="ACCRA" id="1020515"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Venus Remedies Ltd" id="1021105"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd" id="1023252"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nectar Lifesciences Ltd" id="1027927"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Suzhou Wanqing Pharm Company Limited" id="1030440"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvest Lodge Ltd" id="1031314"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Central South University" id="1033512"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="OpGen Inc" id="1037351"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University Hospitals Case Medical Center" id="1043115"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangnan University" id="1043874"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Meiji Holdings Co Ltd" id="1046809"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hainan Meida Pharmaceutical Co. Ltd." id="1053495"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CordenPharma International GmbH" id="1054634"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Curetis AG" id="1055723"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shandong Boyuan Chemical Co Ltd" id="1068648"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="VenatoRx Pharmaceuticals Inc" id="1070587"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nanjing Yoko Pharmaceutical Co Ltd" id="1074506"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Suzhou Zhonglian Chemical Pharmaceutical Co Ltd" id="1075335"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Amity University" id="1086373"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hetero Group" id="1087006"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Perrigo Co plc" id="1091305"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Cells For Cells" id="1100245"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wuxi JieshengJiekang Biotech Co Ltd" id="1108089"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Avails Medical Inc" id="1109680"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Boulos &amp; Cooper Pharmaceuticals Pty Ltd" id="1122067"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Qiqihar Medical University" id="1122375"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Veratin Pty Ltd" id="1145562"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ares Genetics GmbH" id="1160172"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Adcock Ingram Ltd" id="13717"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bristol-Myers Squibb Co" id="15065"></CompanyLink><CountAsOwner>7</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Daewoong Pharmaceutical Co Ltd" id="15587"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck KGaA" id="18101"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="US Government" id="20516"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Case Western Reserve University" id="20553"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universitat des Saarlandes" id="20672"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="ACS Dobfar SpA" id="21883"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lupin Ltd" id="21932"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Memorial Sloan-Kettering Cancer Center" id="22122"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wockhardt Ltd" id="27614"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Orchid Pharma Ltd" id="27798"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Basilea Pharmaceutica International Ltd" id="28104"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alembic Ltd" id="29955"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Aurobindo Pharma Ltd" id="30215"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput>